Radacic M, Overgaard J, Skaric D, Skaric V, Horsman M
Department of Experimental Clinical Oncology, Danish Cancer Society, Aarhus.
Acta Oncol. 1993;32(1):53-6. doi: 10.3109/02841869309083885.
The ability of tetrahydroindazolone carboxylic acid (HIDA) to reduce the toxicity of cis-diamminedichloroplatinum (cis-DDP) in CDF1 mice was investigated. Toxicity was assessed both in terms of mouse lethality occurring within 14 days after treatment and kidney damage estimated by measurement of plasma urea. The levels of plasma urea were found to increase from day 2 after intraperitoneal (i.p.) injection of cis-DDP, reaching a peak at day 5. This increase was also cis-DDP-dose dependent. An i.p. injection of HIDA reduced kidney damage only when given 2.5 h prior to cis-DDP and at HIDA doses of 100 mg/kg or larger. The protection ratio for this reduction was 1.10. HIDA also decreased mouse lethality from cis-DDP, resulting in a PR of 1.41. This protective effect of HIDA on cis-DDP toxicity may eventually have a clinical application.
研究了四氢吲唑酮羧酸(HIDA)降低顺二氯二氨铂(顺铂)对CDF1小鼠毒性的能力。通过治疗后14天内小鼠的致死率以及通过测量血浆尿素来评估肾脏损伤这两方面来评估毒性。发现腹腔注射顺铂后第2天血浆尿素水平开始升高,在第5天达到峰值。这种升高也呈顺铂剂量依赖性。仅当在顺铂给药前2.5小时以100mg/kg或更大剂量腹腔注射HIDA时,其可减轻肾脏损伤。这种降低的保护率为1.10。HIDA还降低了顺铂导致的小鼠致死率,保护率为1.41。HIDA对顺铂毒性的这种保护作用最终可能具有临床应用价值。